Lilly's triple-hormone weight-loss drug sparks record losses in phase 3 trial

Lilly reports that retatrutide, a triple agonist of GLP-1, GIP, and glucagon, produced up to about 85 pounds (roughly 30% of body weight) loss in a phase 3 trial of ~2,300 people with obesity or overweight, with the highest weekly dose averaging 28% weight loss over 80 weeks (some participants continued to 104 weeks). If approved, it could surpass current GLP-1 meds and aid patients who don’t respond to those drugs. Side effects include nausea, GI issues, skin sensations, and UTIs. Full results haven’t been published in a medical journal, and an FDA filing could occur as early as this year.